Speaker Profile
M.D., MBA, Co-Founder, Q Bio
Biography
Garry Choy, MD, MS, MBA is a physician-executive with experience across startups, health technology, payer organizations, and care delivery systems. His work has spanned product development, clinical quality improvement, provider data and network management, regulatory and medical affairs, clinical operations, commercialization, healthcare informatics, and data science.
Dr. Choy is a Co-Founder of Q Bio and previously served as its first Chief Medical Officer. He is also Co-Founder and former CMO/CCO of CredSimple (now Andros) and previously served as Assistant CMIO for Advanced Technologies at Massachusetts General Physicians Organization. He currently serves as Chief Clinical Transformation Officer within Enterprise Medical Affairs at UnitedHealth Group (Optum and UnitedHealthcare). Dr. Choy has served as faculty at Harvard Medical School and Harvard College and trained at Columbia, Stanford, Johns Hopkins, Albert Einstein College of Medicine, Brigham and Women’s Hospital, and Massachusetts General Hospital.
Talk
Q Bio - Operating System for Preventative Diagnostics
Overview and experience of how Q Bio has partnered with health systems to enable longevity and preventive-care programs through the Q Exam—an evidence-based assessment combining whole-body MRI with integrated blood, urine, and genetic biomarkers. The Q Exam establishes a longitudinal baseline for risk assessment, early disease detection, and more informed clinical decision-making over time.
AI and Data Sciences Showcase:
Q Bio
Q Bio provides the technology, analytics, and operational infrastructure to deliver the Q Exam—combining whole-body MRI and integrated biomarkers—to establish longitudinal baselines for preventive and longevity care and support scalable, provider-branded premium programs.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
